This morning at a meeting in Washington, D.C., researchers from the academia, the Food and Drug Administration, the National Cancer Institute, a leading patient advocacy group and several drug companies are describing a new clinical trial in lung cancer that could fundamentally change the way cancer drugs are studied and approved, speeding medicines that target specific genetic mutations in cancer toward the market and patients.
Hey, check out all the research scientist jobs. Post your resume today!
